ClinicalTrials.gg
CompletedNCT03847974Updated Mar 2, 2022Results posted

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

A Phase 2 interventional study of LIB003 in Hypercholesterolemia, sponsored by LIB Therapeutics LLC. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.

Sponsored by LIB Therapeutics LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 379 studies in Hypercholesterolemia with a site in United States — 32 open to participants now, 42 under way, 11 of them phase 3. Hypercholesterolemia · United States.

Enrollment
285th of 347
32 · median 120
Started
2019
with 5 others
Phase 2
66 of 379
5 open now
Registered
282nd of 379
by date

Among the 379 studies in Hypercholesterolemia with a site in United States, this one is the 285th largest by enrollment of the 347 interventional ones that give a count, is one of 6 that started in 2019, is one of 66 in phase 2, and was the 282nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

32 of the 379 studies in Hypercholesterolemia with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 379 studies in Hypercholesterolemia with a site in United States, or all of them as a file.
02

Study summary

To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)

Read the detailed description

To assess the longer term safety, tolerability, immunogenicity, PK, PD and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W) in patients on stable maximally tolerated statins with or without ezetimibe who completed the phase 2 dose ranging trial LIB003-002

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. men and women 18 years or older
  2. Elevated LDL-C on current lipid lowering therapy and; prior atherosclerotic cardiovascular disease (CVD) event or evidence of CVD or without CVD but at high risk for CVD based on American Heart Association/American College of Cardiology (AHA/ACC) CVD risk calculator, or aged 40 years and older with diabetes and moderate- to high-intensity statin, or pre-treatment LDL-C 190 mg/dL or greater or heterozygous familial hypercholesterolemia (HeFH)
  3. patients who met original entry criteria in, and completed, the double-blind, placebo-controlled 16-week Phase 2 study (LIB003-002)

Exclusion criteria

Exclusion Criteria:

  1. patients who did not who complete the double-blind, placebo-controlled 16-week Phase 2 study (LIB003-002)
  2. \<18 years of age
  3. pregnant or women of not using acceptable
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    LIB003

    LIB003

    Drug: LIB003

Interventions

  • DrugLIB003

    300 mg SC Q4W

    Also known as: lerodalcibep

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    safety and tolerability will be based on the incidence and severity of treatment emergent adverse events

    Time frame: 52 weeks

Secondary outcomes

  1. Percent Change in LDL-C at 52 Weeks

    percent change in serum LDL-C from baseline at 52 weeks

    Time frame: 52 weeks

07

Results

Posted Feb 10, 2022

Participant flow

4 clinical centers in USA, recruitment from patients completing a phase 2 dose ranging trial (LIB003-002)

Participant flow — Overall Study
MilestoneLIB003 (Lerodalcibep)
Started32
Completed26
Not completed6
Withdrew: Relocated out of region3
Withdrew: Withdrawal by subject2
Withdrew: Adverse event1

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

safety and tolerability will be based on the incidence and severity of treatment emergent adverse events

Time frame:
52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsLIB003 (Lerodalcibep)
SAE3
ISRs5
SecondaryPercent Change in LDL-C at 52 Weeks

percent change in serum LDL-C from baseline at 52 weeks

Time frame:
52 weeks
Reported as:
Mean · percentage from baseline
Percent Change in LDL-C at 52 Weeks
percentage from baselineLIB003 (Lerodalcibep)
Percent Change in LDL-C at 52 Weeks64.1 ± 17.4

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LIB003 (Lerodalcibep)0/32 (0%)3/32 (9.4%)28/32 (87.5%)
Most frequent serious events
Most frequent serious events
EventLIB003 (Lerodalcibep)
supraventricular tachycardiaCardiac disorders1/32
small bowel obstructionGastrointestinal disorders1/32
worsening of uterine fibroidsReproductive system and breast disorders1/32
Most frequent other events
Most frequent other events
EventLIB003 (Lerodalcibep)
Other Adverse EventGeneral disorders28/32
Other (Not Including Serious) Adverse Events were not monitored/assessed using specific Adverse EvenSkin and subcutaneous tissue disorders3/32

Baseline characteristics

Subjects with CVD or high risk for CVD on maximally tolerated statin completing 12 week Phase 2 LIB003-002 dose ranging trial

Age, Continuous
Age, Continuous(years)LIB003
Mean63.1 (32 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)LIB003
Female20
Male12
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LIB003
White25
African-American7
Region of Enrollment
Region of Enrollment(Participants)LIB003
United States32
BMI
BMI(kg/m^2)LIB003
Mean30.08 (21.7 to 37.8)
08

Study locations

3 sites
  • Sterling Research Group
    Cincinnati, Ohio 45219, United States
  • The Lindner Research Center
    Cincinnati, Ohio 45219, United States
  • Metabolic & Atherosclerosis Research Center (MARC)
    Cincinnati, Ohio 45227, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Apr 2020, 13 months.

Results were first posted in Feb 2022, 1 year 10 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 13 months is above that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2019
First posted
Feb 20, 2019
StartActual
Feb 14, 2019
Primary completionActual
Apr 7, 2020
CompletionActual
Aug 31, 2020
Results first posted
Feb 10, 2022
Last update
Mar 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03847974
Lead sponsor
LIB Therapeutics LLC
Responsible party
Sponsor
First posted
Feb 20, 2019
Start date
Feb 14, 2019
Primary completion
Apr 7, 2020
Completion
Aug 31, 2020
Results posted
Feb 10, 2022
Last update
Mar 2, 2022

Study contacts

Evan A Stein, MD PhD
study director · LIB Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lerodalcibep

Start the discussion